MULTIPLE MYELOMA COMPLICATED BY CONCOMITANT CARDIAC PATHOLOGY
https://doi.org/10.18821/0234-5730-2017-62-3-140-146
Abstract
Material and methods. 148 patients (69 males, 79 females) with multiple myeloma (MM) and cardiac pathology were included in the study during March 2008 – May 2010. The median age of patients was 64.7 years (ranges 36.3–82.7). The patients were divided in two groups. In the first group the patients with de novo with MM (n = 72) were included. The patients with relapsed or refractory MM (RR; n = 76) were included in the second group.
Results. The bortezomib-containing regimens (VCD, VMP or VD) were used as anti-myeloma treatment. The overall response was documented in 65.7% and 59.5% cases including complete (CR) and strong complete remission (sCR) in 22.9% and 20.3% cases respectively. For a median follow-up of 4.9 years for the comparison groups, the 5-year overall survival (OS) was 22.8 ± 5.3% and 17.3 ± 4.4% (p = 0.295). The median OS was 40 and 31.8 months respectively. In multivariate analysis only ECOG scores ≥ 2 were demonstrated an independent negative prognostic value both for the event-free survival (Hazard ratio 1.69; p = 0.006) and OS (Hazard ratio 1.76; p = 0.003).
Conclusion. The bortezomib-based treatment of MM patients with concomitant cardiac pathology was not accompanied by an increase in the incidence of cardiovascular adverse events.
About the Authors
E. V. Yurova
N.I. Pirogov Russian National Research Medical University
Russian Federation
Moscow, 117997
Russian Federation
Moscow, 117997
S. V. Semochkin
N.I. Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Moscow, 117997
Semochkin Sergey V., MD, PhD, DSci.
References
1. Kaprin A.D., Starinskiy V.V., Petrova G.V., eds. Malignant neoplasms in Russia in 2015 (morbidity and mortality). Moscow: P. Herzen Moscow Scientific Research Oncological Institute; 2017. (in Russian)
2. Mitina T.A., Golenkov A.K., Trifonova E.V., Lutskaya T.D., Kataeva E.V., Vysotskaya L.L., et al. The efficacy of bortezomib, melphalan and prednisolone (VMP) in patients with newly diagnosed multiple myeloma. Medline.ru. 2013; 14(4): 1030–50. (in Russian). http://www.medline.ru/public/art/tom14/art82.html
3. Kaya H., Peressini B., Jawed I., Martincic D., Elaimy A.L., Lamoreaux W.T., et al. Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients. Int. J. Hematol. 2012; 95(1): 64–70.
4. Tim Goodnough L., Comin-Colet J., Leal-Noval S., Ozawa S., Takere J., Henry D., et al. Management of anemia in patients with congestive heart failure. Am. J. Hematol. 2017; 92(1): 88–93.
5. Kwaan H.C. Hyperviscosity in plasma cell dyscrasias. Clin. Hemorheol. Microcirc. 2013; 55(1): 75–83.
6. Kohrt H., Logan A., Temmins C., Witteles R., Liedtke M., Medeiros B., et al. Reversible high-output cardiac failure, an unusual marker of disease status in multiple myeloma. Leuk. Lymphoma. 2008; 49(3): 581–5.
7. Rekhtina I.G., Mendeleeva L.P., Biryukova L.S. Dialysis-dependent renal failure in patients with multiple myeloma: reversible factors. Therapeutic archive. Russian Journal (Terapevticheskiy arkhiv). 2015; 87(7): 72–6. (in Russian)
8. Ukholkina G.B., Kuchin G.A., Bychkova O.P., Chihirev O.A. Amyloidosis of the heart in clinical practice. Heart failure. Russian Journal (Serdechnaya nedostatochnost). 2016; 17(1): 57–68. (in Russian)
9. Smith L.A., Cornelius V.R., Plummer C.J., Levitt G., Verrill M., Canney P., Jones A. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010; 10: 337. doi: 10.1186/1471- 2407-10-337.
10. Kozelj M., Zver S., Zadnik V. Long term follow-up report of cardiac toxicity in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. Radiol Oncol. 2013; 47(2): 161–5.
11. Bagratuni T., Kastritis E., Politou M., Roussou M., Kostouros E., Gavriatopoulou M., et al. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens. Am. J. Hematol. 2013; 88(9): 765–70.
12. Spur E.M., Althof N., Respondek D., Klingel K., Heuser A., Overkleeft H.S., Voigt A. Inhibition of chymotryptic-like standard proteasome activity exacerbates doxorubicin-induced cytotoxicity in primary cardiomyocytes. Toxicology. 2016; 353–354: 34–47.
13. Durie B.G., Salmon S.E. A clinical staging system for multiple myeloma: Correlation of measure Myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975; 36(9): 842–54.
14. Durie B.G., Harousseau J.L., Miguel J.S., Bladу J., Barlogie B., Anderson K., et al. International uniform response criteria for multiple myeloma. Leukemia. 2006; 20(9): 1467–73.
15. U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Published May 28, 2009. Available at: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14._QuickReference_5x7.pdf (accessed 04.04.2017)
16. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. Boston: Brown & Co; 1994: 253–6.
17. Prentice R.L., Kalbfleisch J.D. Mixed discrete and continuous Cox regression model. Lifetime Data Anal. 2003; 9(2): 195–210.
18. Moreau P., Hulin C., Macro M., Caillot D., Chaleteix C., Roussel M., et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016; 127(21): 2569–74.
19. Reeder C.B., Reece D.E., Kukreti V., Mikhael J.R., Chen C., Trudel S., et al. Long-term survival with cyclophosphamide, bortezomib and dexamethasone induction therapy in patients with newly diagnosed multiple myeloma. Br. J. Haematol. 2014; 167(4): 563–5.
20. Chng W.J., Goldschmidt H., Dimopoulos M.A., Moreau P., Joshua D., Palumbo A., et al. Carfilzomib-dexamethasone vs bortezomibdexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study Available at: ENDEAVOR. Leukemia. 2017; 31(6): 1368–74. doi: 10.1038/leu.2016.390. (accessed 06.06.2017)
21. Tuchman S.A., Moore J.O., De Castro C.D., Li Z., Sellars E., Kang Y., et al. Phase II study of dose-attenuated bortezomib, cyclophosphamide and dexamethasone (VCD-Lite) in very old or otherwise toxicity-vulnerable adults with newly diagnosed multiple myeloma. J. Geriatr. Oncol. 2017; 8(3): 165–9. Available at: http://www.geriatriconcology.net/article/S1879-4068(17)30030-9. (accessed 16.06.2017)
22. Rosinol L., Oriol A., Mateos M.V., Sureda A., García-Sánchez P., Gutierrez N., et al. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stemcell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J. Clin. Oncol. 2007; 25(28): 4452–8.
23. Harousseau J.L., Attal M., Leleu X., Troncy J., Pegourie B., Stoppa A.M., et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica. 2006; 91(11): 1498–505.
24. Mateos M.V., Oriol A., Martínez-López J., Teruel A.I., Bengoechea E., Palomera L., et al. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Ann. Hematol. 2016; 95(12): 2033–41.
25. de Waal EG., de Munck L., Hoogendoorn M., Woolthui G., van der Velden A., Tromp Y., et al. Combination therapy with bortezomib, continuous low-dose cyclophosphamide and dexamethasone followed by one year of maintenance treatment for relapsed multiple myeloma patients. Br. J. Haematol. 2015; 171(5): 720–5.
26. Mai E.K, Bertsch U., Dürig J., Kunz C., Haenel M., Blau I.W., et al. Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma. Leukemia. 2015; 29(8): 1721–9.
27. Fu W., Delasalle K., Wang J., Song S., Hou J., Alexanian R., et al. Bortezomib-cyclophosphamide-dexamethasone for relapsing multiple myeloma. Am. J. Clin. Oncol. 2012; 35(6): 562–5.
28. Hajek R., Jarkovsky J., Bouwmeester W., Treur M., DeCosta L., Campioni M., et al. Exploration of Survival Stratification of Patients with Multiple Myeloma after First Relapse Using Real World Data. Blood. 2016; 128(22): Abstract. 2417. Available at: http://www.bloodjournal.org/content/128/22/2417 (accessed 04.06.2017)
29. Lenihan D.J., Potluri R., Bhandari H., Ranjan S., Chen C. Evaluation of cardiovascular comorbidities among patients with multiple myeloma in the United States. Blood. 2016; 128(22): Abstr. 4794. Available at: http://www.bloodjournal.org/content/128/22/4794?ssochecked=true (accessed 04.06.2017)
30. Bahlis N.J., Lazarus H.M. Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted? Bone Marrow Transplant. 2006; 38(1): 7–15.
31. Xiao Y., Yin J., Wei J., Shang Z. Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: a systematic review and meta-analysis. PLoS One. 2014; 9(1): e87671. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906186 (accessed 16.06.2017)
Review
For citations:
Yurova E.V., Semochkin S.V. MULTIPLE MYELOMA COMPLICATED BY CONCOMITANT CARDIAC PATHOLOGY. Russian journal of hematology and transfusiology. 2017;62(3):140-146. (In Russ.) https://doi.org/10.18821/0234-5730-2017-62-3-140-146
Views:
449
Email this article 
